Transforming Paediatric Care: Virtual Care Modalities Prove Effective and Promising in Quebec

By Staff Writer

August 24, 2023

In the face of an ageing population, increased chronic diseases, and limited professional resources, Quebec is turning to virtual care tools to meet the growing demand for home and institutional care. This shift has been further accelerated by the COVID-19 pandemic, which has highlighted the potential of virtual care in specialty medicine. The Quebec Ministry of Health and Social Services (MSSS) has tasked the National Institute for Excellence in Health and Social Services (INESSS) with providing a state-of-knowledge report to guide the use of virtual care in specialty medicine.

The report, which covers seven areas including paediatrics, psychiatry, neurology, haematology/oncology, respirology, general surgery, and internal medicine, is aimed at informing public decision-makers, medical associations, and health and social services professionals about virtual care practices. The findings, based on a scoping review of scientific and grey literature from the past five years, reveal promising results for the use of virtual care modalities in paediatrics.

Virtual care interventions such as teleconsultation, telemonitoring, tele education, teleassistance, and tele intervention have shown effectiveness in assessing, diagnosing, monitoring, and treating a range of paediatric conditions. These include neurodevelopmental disorders, certain cancers, dermatological conditions, and acute conditions requiring emergency or intensive care.

The report also highlights potential benefits of virtual care in improving access to health care for children with chronic illnesses, those in underprivileged areas, and those in remote or rural areas. Patient and care provider satisfaction with virtual care modalities is reported as high, with virtual care deemed as safe and secure as in-person care.

While the report acknowledges limitations, including the need for further quality studies, it underscores the transformative potential of virtual care in paediatrics. As Quebec continues to navigate the challenges of healthcare delivery, virtual care modalities offer a promising pathway to improved patient care and engagement.

Reference url

Recent Posts

DTC telehealth partnerships
           

DTC Telehealth Partnerships: Navigating Risks in Pharma’s Digital Expansion

🚀 Are pharmaceutical companies’ DTC telehealth partnerships reshaping healthcare for better or worse?

Recent findings from the “DTC Investigation 2025” report reveal key insights into the high prescription rates and potential risks of these digital platforms operated by giants like Pfizer and Eli Lilly. Alarmingly, inadequate clinical safeguards raise questions about patient safety, prescribing practices, and cost implications.

Dive into this critical discussion about the intersection of digital health and pharmaceutical practices, and explore what it means for the future of patient care.

#SyenzaNews #DigitalHealth #HealthEconomics #HealthcarePolicy

MAF Test breast cancer
       

MAF Test Breast Cancer: Revolutionizing Personalized Treatment in Spanish Oncology

🌟 How can personalized medicine transform breast cancer treatment in Spain?

The recent rollout of the MAF Test breast cancer in leading Spanish hospitals is set to revolutionize patient care by enabling targeted treatment strategies. This innovative molecular assay not only identifies patients who will benefit from bisphosphonates but also spares those for whom the treatment may be harmful, ultimately improving outcomes for thousands.

Dive into the article to discover how this approach aligns with global trends in oncology and enhances healthcare resource allocation.

#SyenzaNews #precisionmedicine #HealthEconomics #innovation

ribociclib breast cancer guidance
           

NICE’s Ribociclib Breast Cancer Guidance: A New Era for High-Risk Patients in the NHS

🌟 Are we on the brink of transforming breast cancer treatment?

NICE’s latest guidance endorsing ribociclib in combination with an aromatase inhibitor marks a significant advancement for adults facing high-risk early breast cancer. This decision not only promises enhanced survival outcomes but also expands treatment options for patients historically limited to conventional therapies.

Dive into the details of this important development and learn how it may revolutionize patient care in the oncology landscape.

#SyenzaNews #oncology #costeffectiveness #MarketAccess

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.